NCT01805921View on ClinicalTrials.gov

RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

PanAd3-RSV given intra-nasally (high dose)

High dose = 5x10\^10 vp

BIOLOGICAL

MVA-RSV given by intra-muscular injection (high dose)

High dose = 1x10\^8 pfu

BIOLOGICAL

PanAd3-RSV given by intra-muscular injection (high dose)

High dose = 5x10\^10 vp

BIOLOGICAL

PanAd3-RSV given intranasally (low dose)

Low dose = 5x10\^9 vp

BIOLOGICAL

MVA-RSV given by intra-muscular injection (low dose)

Low dose = 1x10\^7 pfu

BIOLOGICAL

PanAd3-RSV given by intra-muscular injection (low dose)

Low dose = 5x10\^9 vp

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
lead

ReiThera Srl

INDUSTRY

NCT01805921 - RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. | Biotech Hunter | Biotech Hunter